Aims: Ethnicity is known to influence patient outcomes and treatment efficacy, but knowledge is limited how multimorbidity interacts with clinical events, for example when heart failure (HF) and atrial fibrillation (AF) combine. Methods and Results: 16,713 patients were included from 12 randomized placebo-controlled trials in HF (11 versus beta-blockers and 1 versus spironolactone), of which 13,568 patients (81.2%) were in sinus rhythm and 3,145 (18.8%) had comorbid AF at baseline. Non-white ethnicity was recorded in 1,899 (11%), with these patients being younger (median age 58 versus 67 years) and suffering higher rates of diabetes, hypertension, and lower left-ventricular ejection fraction (median 25% versus 30%) than those of white ethnicity. During median follow-up of 1.4 years (IQR 0.8-2.3), the primary outcome of all-cause mortality occurred in 394 (21%) non-white patients and 2,142 (15%) white patients, with confounder-adjusted hazard ratio (HR) 1.36, 95% CI 1.20-1.54; p<0.001. The impact of ethnicity on death was greater in patients with coexisting HF and AF (non-white versus white HR 2.05; 95% CI 1.55-2.70; p<0.001) than in those with HF in sinus rhythm (HR 1.24; 95% CI 1.08-1.41; p=0.002). The interaction p-value was 0.003, and confirmed using propensity-score matching to account for baseline differences (p=0.009). Similar disparities for the combination of ethnicity and comorbidity were seen for the secondary outcomes cardiovascular and HF-related death, and cardiovascular and HF-related hospitalisation. Conclusion: Non-white patients with HF suffer from substantially higher rates of death, and comorbid AF leads to significant worsening of this ethnicity-related disparity.
Champsi et al. (Fri,) studied this question.